Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.
The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus.
It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.
Further, the company has supply and distribution agreement with BiommS. A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | 0.05 Increased by +600.00% | 0.05 |
| May 6, 25 | 0.04 Increased by 0.00% | 0.06 Decreased by -33.33% |
| Feb 25, 25 | 0.03 Increased by +493.02% | 0.03 Decreased by -15.00% |
| Nov 7, 24 | 0.05 Increased by +400.00% | 0.03 Increased by +66.67% |
| Aug 7, 24 | -0.01 Increased by +50.00% | 0.01 Decreased by -200.00% |
| May 8, 24 | 0.04 Increased by +200.00% | 0.03 Increased by +33.33% |
| Feb 27, 24 | 0.00 Increased by +106.14% | 0.01 Decreased by -57.00% |
| Nov 7, 23 | 0.01 Increased by +116.67% | -0.02 Increased by +150.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 76.53 M Increased by +5.72% | 668.00 K Increased by +133.17% | Increased by +0.87% Increased by +131.37% |
| Mar 31, 25 | 78.35 M Increased by +18.25% | 13.16 M Increased by +23.78% | Increased by +16.79% Increased by +4.68% |
| Dec 31, 24 | 76.78 M Increased by +31.30% | 7.42 M Increased by +429.76% | Increased by +9.67% Increased by +303.46% |
| Sep 30, 24 | 70.08 M Increased by +36.73% | 11.55 M Increased by +571.12% | Increased by +16.48% Increased by +390.83% |
| Jun 30, 24 | 72.39 M Increased by +48.91% | -2.01 M Increased by +61.75% | Decreased by -2.78% Increased by +74.31% |
| Mar 31, 24 | 66.26 M Increased by +63.10% | 10.63 M Increased by +166.37% | Increased by +16.04% Increased by +140.69% |
| Dec 31, 23 | 58.47 M Increased by +62.16% | 1.40 M Increased by +106.03% | Increased by +2.40% Increased by +103.72% |
| Sep 30, 23 | 51.25 M Increased by +56.14% | 1.72 M Increased by +108.73% | Increased by +3.36% Increased by +105.59% |